Tuesday, February 26th, 2008
A new US study found that women taking combined hormone therapy had an increased risk of otherwise avoidable abnormal mammograms and breast biopsies that compromised the ability of these two methods to help diagnose breast cancer.
The study was carried out by lead author Dr Rowan T Chlebowski, an investigator at ...
Posted in Breast Cancer | No Comments »
Saturday, February 23rd, 2008
ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), announced the acceptance of an abstract describing the results of a study using Xibrom(TM) (bromfenac ophthalmic solution) 0.09% therapy in combination with Lucentis(R) (ranibizumab injection) in patients with age-related macular degeneration (AMD). According to the abstract, patients who received Xibrom required 1.6 +/- 0.69 injections ...
Posted in Eye Health / Optometry | No Comments »
Saturday, February 23rd, 2008
It would "not only be unscientific but unethical" for FDA to reject Genentech's colon and lung cancer treatment Avastin for use as metastatic breast cancer treatment, a Wall Street Journal editorial says (Wall Street Journal, 2/21).
FDA is scheduled to decide Saturday whether to approve Avastin for treatment of metastatic breast ...
Posted in Breast Cancer | No Comments »
Friday, February 22nd, 2008
Scientists at the Gladstone Institute of Virology and Immunology (GIVI) and the University of California, San Francisco (UCSF) have found that therapy can be used to stimulate the production of vital immune cells, called "T- cells," in adults with HIV infection.
HIV disease destroys T-cells, leading to collapse of the immune ...
Posted in Immune System | No Comments »
Tuesday, February 19th, 2008
Among women, breast cancer is the most common cause of cancer death. Each year nearly 180,000 women in the United States are diagnosed with breast cancer. More than 40,000 a year die from this disease*. These facts stress the importance of a quality-ensured early detection of breast cancer as well ...
Posted in Breast Cancer | No Comments »
Tuesday, February 19th, 2008
ProCure Treatment Centers, Inc. and the University of Pennsylvania's Roberts Proton Therapy Center announced an agreement that will provide advanced training programs and accredit medical professionals in proton therapy - an alternative to conventional radiation therapy that avoids many of the side effects inherent in treatment. The agreement focuses on ...
Posted in Cancer / Oncology | No Comments »
Monday, February 18th, 2008
UroToday.com - Dr. Sanda reported on the PROSTQA, which assesses the QOL outcomes for patients treated with RP, XRT and brachytherapy. Sexual, urinary, bowel, and vitality data were collected and analyzed. The study was not randomized and the HRQOL was assessed within groups. Sexual function dropped most for RP patients, ...
Posted in Urology / Nephrology | No Comments »
Monday, February 18th, 2008
UroToday.com - Dr. Sandler reported on a secondary analysis of RTOG 85-31, in which the patients who got longer duration of ADT had better survival. In RTOG 9202, 1,554 men with T3 disease had either ADT for a mean of 28 months vs. short term ADT and there was a ...
Posted in Urology / Nephrology | No Comments »
